Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira ® Biosimilar Hadlima™ (adalimumab-bwwd)

INCHEON, Korea and Jersey City, N.J., United States– August 17, 2022– Samsung Bioepis Co., Ltd. and Organon& Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news